乌帕替尼与托法替布诱导溃疡性结肠炎缓解的疗效比较：真实世界数据 - Suppr

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

作者信息

Boneschansker Leo, Ananthakrishnan Ashwin N

机构信息

Massachusetts General Hospital Crohn's and Colitis Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2427-2429.e1. doi: 10.1016/j.cgh.2023.03.040. Epub 2023 Apr 7.

DOI:10.1016/j.cgh.2023.03.040

PMID:37031712

Abstract

摘要

相似文献

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2427-2429.e1. doi: 10.1016/j.cgh.2023.03.040. Epub 2023 Apr 7.

Efficacy of JAK inhibitors in Ulcerative Colitis.

J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S737-S745. doi: 10.1093/ecco-jcc/jjz202.

Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.

World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929.

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.

Dig Liver Dis. 2020 Mar;52(3):268-273. doi: 10.1016/j.dld.2019.10.003. Epub 2019 Nov 13.

Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy.

Inflamm Bowel Dis. 2024 May 2;30(5):868-870. doi: 10.1093/ibd/izae076.

Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.

Dig Dis Sci. 2024 Oct;69(10):3911-3919. doi: 10.1007/s10620-024-08630-3. Epub 2024 Sep 9.

Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies.

Dig Liver Dis. 2022 Feb;54(2):183-191. doi: 10.1016/j.dld.2021.04.018. Epub 2021 May 16.

Is tofacitinib a game-changing drug for ulcerative colitis?

United European Gastroenterol J. 2020 Aug;8(7):755-763. doi: 10.1177/2050640620935732. Epub 2020 Jun 18.

Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management.

World J Gastroenterol. 2024 Sep 21;30(35):3942-3953. doi: 10.3748/wjg.v30.i35.3942.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

引用本文的文献

Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies.

Pharmgenomics Pers Med. 2025 Sep 5;18:219-238. doi: 10.2147/PGPM.S536459. eCollection 2025.

Effectiveness of upadacitinib in ulcerative colitis patients with prior tofacitinib exposure: a systematic review and meta-analysis.

Ann Gastroenterol. 2025 Sep-Oct;38(5):511-518. doi: 10.20524/aog.2025.0991. Epub 2025 Aug 14.

Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis.

J Ophthalmic Vis Res. 2025 May 5;20. doi: 10.18502/jovr.v20.14952. eCollection 2025.

JAK Inhibitor and Crohn's Disease.

Biomedicines. 2025 May 29;13(6):1325. doi: 10.3390/biomedicines13061325.

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.

Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22.

Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.

J Clin Med. 2025 Mar 25;14(7):2232. doi: 10.3390/jcm14072232.

Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative Colitis Including Intestinal Ultrasound Assessment: A Multicenter, Real-World Observational Study.

J Clin Med. 2025 Mar 3;14(5):1695. doi: 10.3390/jcm14051695.

Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure.

J Clin Gastroenterol. 2025 Mar 6. doi: 10.1097/MCG.0000000000002157.

Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases - A meta-analysis of randomized controlled trials.

Indian J Gastroenterol. 2025 Apr;44(2):154-162. doi: 10.1007/s12664-024-01720-0. Epub 2025 Feb 8.

Real-World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study.

United European Gastroenterol J. 2024 Dec;12(10):1357-1366. doi: 10.1002/ueg2.12704. Epub 2024 Nov 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

作者信息

Boneschansker Leo, Ananthakrishnan Ashwin N

机构信息

Massachusetts General Hospital Crohn's and Colitis Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2427-2429.e1. doi: 10.1016/j.cgh.2023.03.040. Epub 2023 Apr 7.

DOI:10.1016/j.cgh.2023.03.040

PMID:37031712

Abstract

摘要

相似文献

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2427-2429.e1. doi: 10.1016/j.cgh.2023.03.040. Epub 2023 Apr 7.

Efficacy of JAK inhibitors in Ulcerative Colitis.

J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S737-S745. doi: 10.1093/ecco-jcc/jjz202.

Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.

World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929.

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.

Dig Liver Dis. 2020 Mar;52(3):268-273. doi: 10.1016/j.dld.2019.10.003. Epub 2019 Nov 13.

Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy.

Inflamm Bowel Dis. 2024 May 2;30(5):868-870. doi: 10.1093/ibd/izae076.

Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.

Dig Dis Sci. 2024 Oct;69(10):3911-3919. doi: 10.1007/s10620-024-08630-3. Epub 2024 Sep 9.

Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies.

Dig Liver Dis. 2022 Feb;54(2):183-191. doi: 10.1016/j.dld.2021.04.018. Epub 2021 May 16.

Is tofacitinib a game-changing drug for ulcerative colitis?

United European Gastroenterol J. 2020 Aug;8(7):755-763. doi: 10.1177/2050640620935732. Epub 2020 Jun 18.

Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management.

World J Gastroenterol. 2024 Sep 21;30(35):3942-3953. doi: 10.3748/wjg.v30.i35.3942.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

引用本文的文献

Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies.

Pharmgenomics Pers Med. 2025 Sep 5;18:219-238. doi: 10.2147/PGPM.S536459. eCollection 2025.

Effectiveness of upadacitinib in ulcerative colitis patients with prior tofacitinib exposure: a systematic review and meta-analysis.

Ann Gastroenterol. 2025 Sep-Oct;38(5):511-518. doi: 10.20524/aog.2025.0991. Epub 2025 Aug 14.

Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis.

J Ophthalmic Vis Res. 2025 May 5;20. doi: 10.18502/jovr.v20.14952. eCollection 2025.

JAK Inhibitor and Crohn's Disease.

Biomedicines. 2025 May 29;13(6):1325. doi: 10.3390/biomedicines13061325.

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.

Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22.

Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.

J Clin Med. 2025 Mar 25;14(7):2232. doi: 10.3390/jcm14072232.

Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative Colitis Including Intestinal Ultrasound Assessment: A Multicenter, Real-World Observational Study.

J Clin Med. 2025 Mar 3;14(5):1695. doi: 10.3390/jcm14051695.

Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure.

J Clin Gastroenterol. 2025 Mar 6. doi: 10.1097/MCG.0000000000002157.

Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases - A meta-analysis of randomized controlled trials.

Indian J Gastroenterol. 2025 Apr;44(2):154-162. doi: 10.1007/s12664-024-01720-0. Epub 2025 Feb 8.

Real-World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study.

United European Gastroenterol J. 2024 Dec;12(10):1357-1366. doi: 10.1002/ueg2.12704. Epub 2024 Nov 13.

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.

作者信息

机构信息

出版信息

相似文献

引用本文的文献